

NEWS RELEASE

Telo Genomics Announces former Roche Executive as Lead Director

Toronto, Ontario, December 05, 2019 – Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce Guido Baechler as the Company’s Lead Director. Mr. Baechler joined the Company’s board of directors at the last AGM and will now head TELO’s board committees tasked to develop and refine the Company’s corporate strategy, including commercialization & partnerships.

“Telo Genomics is leveraging a ground breaking liquid biopsy technology to create diagnostic and prognostic solutions that offer better information and better treatment for patients. Targeting critical unmet healthcare needs to improve patient outcomes is our goal,” said Mr. Baechler, Lead Director of TELO. “Telo Genomics’ first liquid biopsy product will focus on the prediction of progression from Multiple Myeloma precursors to full blown Multiple Myeloma, and prediction of response to first-line therapy at the point of diagnosis.”

Mr. Baechler has over 25 years of experience working with emerging technologies in the life sciences and medical diagnostics industries. He is a visionary executive with global experience in both start-up and leading multinational organizations. Most recently, he served as president, chief executive officer, and director of Singulex, Inc. Prior to Singulex, Mr. Baechler worked at Roche Diagnostics in both the U.S. and Europe where he held leadership and executive positions at both Roche Diagnostics Europe and Roche Molecular Diagnostics.

“We are very excited to have Mr. Baechler as the Company’s lead director. Mr. Baechler is a veteran in the life sciences industry and brings a tremendous amount of diagnostic commercialization experience to Telo Genomics,” commented Hugh Rogers, chairman of TELO. “This is a major step forward for the Company as we aim to advance our clinical programs with a focus on product development and commercialization.”

About Telo Genomics

Telo Genomics (TELO) is a world leader in the quantitative analysis of telomeres, with a particular focus on liquid biopsy diagnostics and prognostics. Its proprietary platform technology has the potential to be a powerful healthcare tool to improve the diagnosis and treatment of several cancers and neurological diseases. TELO employs a proprietary software platform, TeloView™, to precisely quantify specific features of patient’s telomeres in three dimensions. This technology has been successful in detecting early disease, determining the aggressiveness and progression of disease and providing powerful insights to guide therapy and treatment protocols, all of which should contribute to improved clinical outcomes for patients. TELO benefits from over 20 years of foundational and translational academic research conducted by the Company’s founder providing a wealth of more than 150 peer reviewed publications, 25 clinical studies involving more than 3,000 patients and 20 different cancers and Alzheimer’s disease.

For further information, please contact:

Hugh Rogers

Chairman

416-673-8487

info@telodx.com

MaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7

www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. news wire services or dissemination in the United States.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the consolidation, the offering, the use of proceeds are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.